PAX-2在子宫内膜增生性病变和I型子宫内膜癌中的表达及意义

Expression of PAX2 in endometrial hyperplastic lesions and type I endometrial carcinomas and its significance

目的:探讨PAX-2在子宫内膜增生性病变及I型子宫内膜癌中的表达及意义。方法:收集正常增殖期子宫内膜31例、良性子宫内膜增生107例、子宫内膜上皮内瘤变58例、子宫内膜样癌76例,采用免疫组织化学法检测PAX-2在上述病变中的表达。结果:PAX-2在上述4组病变组织中的正常表达率逐渐降低,分别为77.4%(24/31),7.5%(8/107),1.7%(1/58),0.0%(0/76),差异有统计学意义(χ~2=142.512,P<0.01)。结论:PAX-2表达缺失参与子宫内膜样癌的发生,而且是其早期事件。PAX-2表达缺失不能作为子宫内膜增生性病变的标志物,但完全缺失可以作为标志物。

Objective: To investigate the expression of PAX-2 in endometrial hyperplastic lesions and type Ⅰendometrial carcinoma and its significance. Methods: Thirty-one cases of normal proliferative endometrium, 107 cases of benign hyperplastic endometrium, 58 cases of endometrioid intraepithelial neoplasia, and 76 cases of endometrioid carcinoma were enrolled. PAX-2 expression was detected by immunohistochemistry in the above mentioned lesions. Results: The normal expression rates of PAX-2 were gradually decreased in proliferative endometrium, benign hyperplastic endometrium, endometrioid intraepithelial neoplasia, and endometrioid carcinoma, with the rates of 77.4%(24/31), 7.5%(8/107), 1.7%(1/58), 0.0%(0/76), respectively. The difference was statistically significant (χ^2 =142.512, P<0.01). Conclusion: The loss of PAX-2 expression plays an important role in the carcinogenesis of endometrioid carcinoma and is an early event. The complete loss of PAX-2 expression is a reliable marker of endometrial hyperplastic lesions rather than the loss of PAX-2 expression.